drugs glp 1 Comparing Ozempic, Wegovy and Other GLP-1 How GLP-1 drug semaglutide may

What is next in the Evolution of GLP-1-based Therapies for Diabetes and Obesity

But until now, there hasnt been any data from large epidemiologic studies. Results showed use of GLP-1 agonists compared with bupropion-naltrexone correlated with a 9.09 (95% CI, 1.25-66), 4.22 (95% CI, 1.02-17.4) and 3.67 (95% CI, 1.15-11.9) times higher risk for pancreatitis, bowel obstruction and gastroparesis, respectively

However, the medication discontinuation rates were greater than 50% across all doses compared to 40% with placebo, with the most common adverse events (AE) being gastrointestinal in nature [27]

We know it's a blow

But for patients trying to understand their options, the picture is no longer as simple as it once was